CONFLICTS OF INTEREST:
No potential competing interest was declared by the authors
- Pemmaraju N, Konopleva M. Approval of tagraxofusp-erzs for blastic
plasmacytoid dendritic cell neoplasm.
Blood
Adv. 2020 Aug 25; 4(16): 4020–4027.
- Agha ME, Monaghan SA, Swerdlow SH. Venetoclax in a patient with a
blastic plazmasitoid dendritic cell neoplasm (BPDCN), N. Engl J
Med.379(2018)1479-1482.
- DiNardo CD, Pratz K, Pullarkart V et al. Venetoclax combined with
decitabine or azacitidine in treatment-naive, elderly patients with
acute myeloid leukemia.Blood. 2019
Jan 3; 133(1): 7–17.
- Arber AD, Orazzi A, Hasserjian R et al. The 2016 revision to the World
Health Organization classification of myeloid neoplasms and acute
leukemia. Blood (2016) 127 (20): 2391–2405
- Jegalian AG, Buxbaum MP, Facchetti F et al. Blastic plasmacytoid
dendritic cell neoplasm in children: diagnostic features and clinical
implications. Haematologica 2010;95(11):1873-9.
- Li Y, Sun V, Sun W et al. Blastic plasmacytoid dendritic cell neoplasm
in children. Hematol Oncol Clin N AM 34(2020)601-612.
- Sakashita K, Saito S, Yanagisawa R et al. Usefulness of allogeneic
stem cell transplantation in first complete remission for pediatric
blastic plasmacytoid dendritic cell neoplasm with skin involvement: A
case report and review of literature. Pediatr Blood Cancer
2013;60(11):E140-2.
- Beziat G, Ysebaert L. Tagraxofusp for the treatment of blastic
plasmacytoid dendritic cell neoplasm(BPDCN): A brief report on
emerging data. Oncotargets and Therapy (2020):13;5199-5205.
- Beziat G, Ysebaert L., Gaudin C et al. venetoclax to treat blastic
plasmacytoid dendritic cell neoplasm: A case-report and a review of
literature. Leukemia Research 85(2019)106199.
- Piccini M, Loscocco GG, Gianfaldoni G et al. Quick complete response
achievement with venetoclax and azacitidine in a case of relapsed
disseminated blastic plasmacytoid dendritic cell neoplasm. Annals of
Hematology (2020) 99:907–909.